29 results about "Endothelial progenitor cell" patented technology

The invention discloses a new application of Apo-EVs, and particularly discloses an application of Apo-EVs from endothelial cells (ECs) in promoting differentiation of endothelial progenitor cells (EPCs) and wound healing. The Apo-EVs is rich in miR-30a-5p, and can significantly promote the differentiation of EPCs to ECs and accelerate the angiogenesis through targeted regulation of EGFR / PI3K / AKT / VEGF signal channels. In a mouse wound healing model, the Apo-EVs is adopted for intervention, and the wound healing time can be effectively shortened. The invention provides a natural, efficient and low-toxicity wound repair biological agent, and provides a new strategy for treatment of ischemic diseases and refractory wounds.

This invention relates to an intravascular blood flow guiding device with an endothelialization-promoting coating. After the coating is applied to the surface of the blood flow guiding device, it can regulate the biological functions of circulating endothelial progenitor cells within the blood vessel, including promoting oriented extracellular matrix formation, promoting cell-extracellular matrix adhesion, and promoting endothelial cell proliferation and maturation. This results in: enhanced adhesion, proliferation, and migration capabilities of endothelial progenitor cells; significantly improved acceleration of the endothelialization process; excellent anti-platelet and anti-SMC adhesion properties; and, combined with the hemodynamic optimization effect of the blood flow guiding device, accelerated functional remodeling of the tumor-bearing artery.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The present technology comprises isolated endothelial progenitor cell (EPC) populations and mesenchymal stem cell (MSC) populations, and methods of making and using the same for treating bleeding disorders, including Von Willebrand Disease, and associated symptoms.

A health care apparatus (2, 2'), used for transmitting a low-frequency wave (W) to the spine or umbilicus so as to increase the number of endothelial progenitor cells (EPCs) and reduce the number of circulating endothelial cells (CECs), thus reducing the risk of cardiovascular-related adverse events. The health care apparatus (2, 2') comprises a box body (21, 21') and a power supply (22, 22'), a speed controller (23, 23'), a rotary mechanism (24, 24'), a connecting rod mechanism (25, 25'), a knocker (26, 26'), and a conical platform (27, 27') which are provided in the box body (21, 21'). The power supply (22, 22') is electrically connected to the speed controller (23, 23') so as to output power to the speed controller (23, 23'). The speed controller (23, 23') is electrically connected to the rotary mechanism (24, 24') and controls rotation of the rotary mechanism (24, 24') at a predetermined speed. The rotary mechanism (24, 24') is connected to the knocker (26, 26') by means of the connecting rod mechanism (25, 25') so as to drive the knocker (26, 26') to knock on a flat surface of the conical platform (27, 27'), and the knocker (26, 26') generates a low-frequency wave (W) of a predetermined frequency. Further provided is the use of the health care apparatus (2, 2') in transmitting a low-frequency wave (W) to the spine or umbilicus.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention discloses a cell therapy drug for treating diseases related to steatosis. The cell therapy drug comprises endothelial progenitor cells or endothelial cells derived from iPSC differentiation. This invention demonstrates that intravenous injection of iPSC-derived endothelial progenitor cells into an animal model of fatty liver disease can treat fatty liver disease by reducing steatosis in liver tissue. The research findings of this invention provide a novel treatment approach for clinical treatment of diseases related to steatosis, especially fatty liver disease.

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

The present invention relates to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases comprising the same, and more specifically, to an umbilical cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases, the present invention relates to a high-purity umbilical cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen characteristics, a method for obtaining an umbilical cord blood-derived vascular endothelial progenitor cell by pre-treating umbilical cord blood, and a composition for preventing and treating ischemic diseases comprising the umbilical cord blood-derived vascular endothelial progenitor cell. The high-purity umbilical cord blood-derived vascular endothelial progenitor cell of the present invention exhibits colony formation, high proliferation ability, and high potential for angiogenesis in vivo, and thus can exhibit an excellent effect on the prevention or treatment of various ischemic diseases induced by blood vessel contraction or occlusion.

The invention relates to the technical field of biomedicine, in particular to an automatic analysis and risk assessment system and method for peripheral blood endothelial progenitor cells, and the method comprises the following steps: collecting a peripheral blood sample and clinical data of a subject; the method comprises the following steps: enriching CD34 + cells from a peripheral blood sample based on microfluidic-immunomagnetic bead enrichment, carrying out VEGFR2 and DAPI immunofluorescent staining on the enriched cells, and obtaining a multi-channel fluorescent digital image; analyzing the multi-channel fluorescent digital image, identifying and counting VEGFR < 2 + > and DAPI < + > double-positive cells to obtain an EPC counting result; inputting the EPC counting result and clinical data of the subject into a multi-modal AI risk assessment model to obtain a risk assessment result; the health management suggestion information is formulated based on the risk assessment result, so that the model can have better suitability with the target subject, and the accuracy of risk assessment is improved.

A health care device and an use thereof are configured to transmit a low frequency wave to a spine or navel to increase the number of endothelial progenitor cells (EPC) and to reduce the number of the circulating endothelial cells (CEC), which may reduce the risk of cardiovascular-related adverse diseases. The health care device includes a box body, a power supply, a speed controller, a rotating mechanism, a linkage mechanism, a knocker and a conical table. The power supply is electrically connected to the speed controller to output electricity to the speed controller. The speed controller is electrically connected to the rotating mechanism and controls the rotating mechanism to rotate at a predetermined speed. The rotating mechanism is connected to the knocker to drive the knocker to knock a flat surface of the conical table. The knocker generates the low frequency wave with a predetermined frequency.

The present disclosure relates to a cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases containing the same, and more specifically, to a highly pure cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen properties, a method for obtaining a cord blood-derived vascular endothelial progenitor cell through preprocessing of cord blood, and a composition for preventing or treating ischemic disease containing the cord blood-derived vascular endothelial progenitor cell. The high-purity cord blood-derived vascular endothelial progenitor cell of the present disclosure exhibits colony formation and high proliferation ability and angiogenic potential in the body, and thus can exhibit excellent effects in the prevention or treatment of various ischemic diseases caused by vascular contraction or occlusion.

Methods for treating and / or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.

The present technology includes an isolated population of endothelial progenitor cells (EPCs) comprising PROCR + / -PDGFRA + / -EPC and a population of mesenchymal stem cells (MSCs), as well as methods of preparation and use thereof in the treatment of hypoxic ischemic encephalopathy (HIE) or brain injury in a subject.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

Using adults stem cells (ASC) including hematopoietic cell (HSC), endothelial progenitor cells and mesenchymal (MSC) stem cells; mobilizing ASC cells into the vascular system using a collection system of one of: (i) an apheresis. (ii) bone marrow; or (iii) direct collection of ASC from the peripheral blood; providing the ASC with a cryopreservation conservation container of about minus 80 degrees centigrade collecting the ASC for defrosting and placed in a sterile container; reprogramming stem cells (RSC) including at least one of (i) RSC by methylation patterns of DNA such as JMJD3 and HDAC; (ii) RSC by acetylation patterns of DNA such as HDAC; (iii) epigenetic programming with a protein of interest (ncRNA); using vectors of AAV or CMV to transfer to specific genes to provide proteins to enlarge physical conditions to lost during the aging process.

Therapeutic formulations and protocols for enhancement of hepatic regeneration, reduction / reversion of liver failure, and restoration of hepatic characteristics of young liver including augmented production of digestive enzymes, production of complement, and detoxificiation. In one embodiment endothelial progenitor cells are cultured in vitro under conditions capable of stimulating enhanced production of microvesicles such as exosomes and / or regenerative factors. Endothelial cells can be activated to produce regenerative factors and / or exosomes by exposure to toll like receptor agonists. Endothelial cells may be autologous, allogeneic or xenogeneic to the recipient.

Method for producing a three-dimensional human multiple myeloma model. The present invention relates to a method for producing a three-dimensional (3D) model of multiple myeloma (MM), in the form of spheroids, by co-culturing mesenchymal stem / stromal cells, endothelial progenitor cells, and primary plasma cells from MM patient(s). The present invention also relates to the spheroids obtained by said method and their uses. Figure for abstract: none

The present disclosure relates to a cord blood-derived vascular endothelial progenitor cell and a composition for preventing or treating ischemic diseases containing the same, and more specifically, to a highly pure cord blood-derived vascular endothelial progenitor cell exhibiting specific surface antigen properties, a method for obtaining a cord blood-derived vascular endothelial progenitor cell through preprocessing of cord blood, and a composition for preventing or treating ischemic disease containing the cord blood-derived vascular endothelial progenitor cell. The high-purity cord blood-derived vascular endothelial progenitor cell of the present disclosure exhibits colony formation and high proliferation ability and angiogenic potential in the body, and thus can exhibit excellent effects in the prevention or treatment of various ischemic diseases caused by vascular contraction or occlusion.

This method for producing vascular endothelial cells derived from pluripotent stem cells comprises: a preparation step for preparing vascular endothelial progenitor cells derived from pluripotent stem cells; and a stress application step for applying a fluid shear stress to the vascular endothelial progenitor cells.

Using adults stem cells (ASC) including hematopoietic cell (HSC), endothelial progenitor cells and mesenchymal (MSC) stem cells; mobilizing ASC cells into the vascular system using a collection system of one of: (i) an apheresis. (ii) bone marrow; or (iii) direct collection of ASC from the peripheral blood; providing the ASC with a cryopreservation conservation container of about minus 80 degrees centigrade collecting the ASC for defrosting and placed in a sterile container; reprogramming stem cells (RSC) including at least one of (I) RSC by methylation patterns of DNA such as JMJD3 and HDAC; (II) RSC by acetylation patterns of DNA such as HDAC; (iii) epigenetic programming with a protein of interest (ncRNA); using vectors of AAV or CMV to transfer to specific genes to provide proteins to enlarge physical conditions to lost during the aging process.

The invention relates to the field of biomedical engineering and disease model construction, in particular to a construction method and application of a full-spectrum liver organoid. The construction method comprises the following steps: respectively differentiating induced pluripotent stem cells from human umbilical cord to obtain transitional hepatic endoderm cells, endothelial progenitor cells, red myeloid progenitor cells, hepatic stellate cells and diaphragm mesenchymal stem cells; transition hepatic endoderm cells, endothelial progenitor cells, red myeloid progenitor cells, hepatic stellate cells and diaphragm mesenchymal stem cells are inoculated into a 3D culture system according to the cell number ratio of (9-11): (6-8): (1-2): (1-2): (1-2); and performing self-assembly co-culture on the seed cells in a 3D culture system until the liver function is mature, thereby obtaining the full-spectrum liver organoid. The technical problem that physiological authenticity, functional integrity and application universality of an existing liver model need to be improved is solved.

The present invention relates to: umbilical cord blood-derived endothelial progenitor cells; and a composition for preventing or treating ischemic diseases, the composition comprising the umbilical cord blood-derived endothelial progenitor cells, and more specifically, to high-purity umbilical cord blood-derived endothelial progenitor cells exhibiting specific surface antigen characteristics, a method for obtaining the umbilical cord blood-derived endothelial progenitor cells through pretreatment of umbilical cord blood, and a composition for preventing or treating ischemic diseases, the composition comprising the umbilical cord blood-derived endothelial progenitor cells. The high-purity umbilical cord blood-derived endothelial progenitor cells according to the present invention exhibit colony formation, high proliferative capacity, and in vivo angiogenesis potential, and thus can exhibit excellent effects in preventing or treating various ischemic diseases caused by vasoconstriction or occlusion.

The present invention addresses the problem of providing a method for forming a complex tissue structure and preparing a liver organoid that faithfully reproduces a healthy liver in which a pathological state can be mimicked by a simple process, and further providing a simple method for preparing a steatotic liver disease model organoid in which it is possible to reproduce the degeneration and complex hepatopathy that are specific to steatotic liver disease.　Provided is a method for producing a multilayered liver organoid, said method including: a cocultivation step for cocultivating source cells; a differentiation inducement step for inducing differentiation of the source cells; and a tissue construction step for constructing a tissue structure that is composed of a plurality of layers of cells, wherein the source cells include hepatoblasts, vascular endothelial progenitor cells, and mesenchymal cells.

This invention relates to the field of biomaterials technology, and more particularly to a method for preparing cRGD-targeted peptide-modified biomimetic nanovesicles derived from endothelial progenitor cells. The preparation method includes the following steps: S1, preparing EPC-NVs; S11, isolating, culturing, and identifying EPCs; S12, preparing EPCs-NVs; S13, modifying and identifying EPC-NVs with cRGD; S2, preparing ADM-Fe 3+ @PA / Ge lma hydrogel: S21, Fe synthesized in an environment with a pH of 10 at a molar ratio of 1:3. 3+ @Original catechin aldehyde solution; S22, Fe from the combined vehicle 3+ @The original catechuic aldehyde solution was mixed with ADM, and after multiple centrifugal washings, the prepared photocurable gelatin (Ge lmA) precursor solution was added; S23, Fe was carried out by ultrasonic cavitation. 3+ @PA's ADM is uniformly dispersed; S24, a double cross-linked hydrogel is formed by irradiation with 416nm blue light and self-assembly of ADM. This method provides a novel biodelivery system with pro-angiogenic, antioxidant, and antibacterial properties, improving the wound treatment effect for diabetes.

This invention discloses the application of endometrial stem cells in fascial repair, belonging to the field of biomedical technology. This invention obtains a combined polypeptide that promotes the co-expression of KGF and LOX through screening. When used separately or in combination with endometrial stem cells and endometrial endothelial progenitor cells, the combined polypeptide effectively promotes the co-expression of KGF and LOX, thereby effectively repairing uterine fascial damage. The combined polypeptide's regulation of the synergistic expression of KGF and LOX in endometrial stem cells and endometrial endothelial progenitor cells improves the efficiency and quality of tissue repair, enabling damaged uterine fascia to recover its normal structure and function more quickly.

This invention relates to the field of biomedical technology, specifically providing an iPSC-induced vascular endothelial progenitor cell and its application in the treatment of atherosclerosis; particularly, the SDF1-linker-VEGF165 fusion protein enhances the application of induced pluripotent stem cell (iPSC)-derived vascular endothelial progenitor cells (EPCs) in the treatment of atherosclerosis. The amino acid sequence of the fusion protein is shown in SEQ ID NO:3, and it connects SDF1 (SEQ ID NO:1) and VEGF165 (SEQ ID NO:2) via a flexible linker (GGGGS×4). Pretreatment of iPSC-induced EPCs (SV-EPCs) with this fusion protein synergistically activates the CXCR4 / VEGFR2 receptor, significantly enhancing cell proliferation activity. In ApoE... ‑ / ‑ In mouse models, SV-EPCs significantly reduced aortic plaque area, showing better results than the single-factor pretreatment group and statin drug group, and significantly improved lipid metabolism. This invention provides a novel cell therapy strategy for atherosclerosis.